

SENATE BILL 144

J1

2lr0533

(PRE-FILED)

By: **Senator Feldman**

Requested: September 22, 2021

Introduced and read first time: January 12, 2022

Assigned to: Finance

A BILL ENTITLED

1 AN ACT concerning

2 **Health – Authorization to Prescribe and Administer Amygdalin – Repeal**

3 FOR the purpose of repealing certain provisions of law relating to the prescription,
4 administration, and regulation of amygdalin; and generally relating to amygdalin.

5 BY repealing

6 Article – Health – General

7 Section 18–302

8 Annotated Code of Maryland

9 (2019 Replacement Volume and 2021 Supplement)

10 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
11 That the Laws of Maryland read as follows:

12 **Article – Health – General**

13 [18–302.

14 (a) Except as provided in subsection (b) of this section, a physician may prescribe
15 or administer amygdalin to treat cancer.

16 (b) (1) A hospital or health facility may not restrict or prohibit the use of
17 amygdalin that a physician, with the consent of a patient, prescribes for or administers to
18 the patient.

19 (2) (i) The Department may restrict or prohibit the use of amygdalin in
20 the treatment of a patient if, after a hearing, the Department finds that the manner in
21 which the amygdalin is prescribed or administered is harmful to the patient.

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.



1 (ii) The Department shall adopt rules and regulations for hearings
2 under this paragraph.

3 (c) The Department and the State Board of Pharmacy shall regulate the
4 manufacture, distribution, and sale of amygdalin for use in this State, but only to ensure
5 that the amygdalin is not adulterated, contaminated by microorganisms, or misbranded.]

6 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect
7 October 1, 2022.